2
ALL2
Nerviano Medical SciencesYear
2
ALL1
20231
2022DEALS // DEV.
2
ALL2
DealsCountry
2
ALL2
ITALY2
ALL1
Italfarmaco S.p.A1
Merck & CoTherapeutic Area
2
ALL2
OncologyStudy Phase
2
ALL1
Phase I1
DiscoveryDeal Type
2
ALL2
Licensing AgreementProduct Type
2
ALL1
Other Small Molecule1
UndisclosedDosage Form
2
ALL2
OralLead Product
2
ALL1
NMS-033052931
UndisclosedTarget
2
ALL1
PARP11
UndisclosedDetails : Under the terms of the agreement, ITF will use NMS’s proprietary linker-payload technology to develop a novel peptide-drug conjugate (PDC) to bring first- and best-in-class personalized medicines to cancer patients.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 14, 2023
Details : NMS-293 has strong potential in combination with a wide variety of DNA-damaging agents, including systemic or targeted chemotherapy (Antibody-Drug Conjugates) or with DNA damage response inhibitors, in numerous tumor types.
Product Name : NMS-293
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 21, 2022